BioCryst: Difference between revisions

From Bhamwiki
Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by the same user not shown)
Line 10: Line 10:
In April [[2023]] BioCryst negotiated a $450 million 5-year financing agreement with Pharmakon Advisors of New York City. The deal provided funds to repay $241.8 million in existing debts to Athyrium Capital Management.
In April [[2023]] BioCryst negotiated a $450 million 5-year financing agreement with Pharmakon Advisors of New York City. The deal provided funds to repay $241.8 million in existing debts to Athyrium Capital Management.


Later that year, BioCryst made plans to expand its research and manufacturing facility to 49,054 square feet, occupying the entire 2100 Riverchase Center building. The [[City of Hoover]] provided $1,828,470 in tax abatements over 10 years to support the expansion.
Later that year, BioCryst made plans to expand its research and manufacturing facility to 49,054 square feet, occupying the entire 2100 Riverchase Center building. The [[City of Hoover]] provided $1,828,470 in tax abatements over 10 years to support the expansion. In early [[2024]] the company announced that it would postpone that expansion amid a larger reduction in research and development spending.


==Chief executives==
==Chief executives==
Line 19: Line 19:
BioCryst has developed several drug treatments:
BioCryst has developed several drug treatments:


* Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
* BCX-1777 ("Fodosine"), IV, for treatment of T-cell leukemia
* Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
* BCX-1812 ("Peramivir"), for treatment of seasonal/life-threatening influenza
* Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
* BCX-4161 ("Avoralstat") for treatment for vision loss related to diabetes
* Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
* BCX-4208 ("Ulodesine"), for treatment of autoimmune diseases/transplantation/Hepatitis C
* BCX-1812 ("Peramivir") for treatment of seasonal/life-threatening influenza (Phase I)
* BCX-7353 ("Orladeyo"), for prevention of recurrent hereditary angioedema attacks
* BCX-4208 Oral, for treatment of autoimmune diseases/transplantation/Hepatitis C (Phase I)
* BCX-7353 ("Orladeyo"), for prevention of recurrent hereditary angioedema attacks (approved by FDA and European Medicines Agency)


==References==
==References==
Line 37: Line 35:
* Patchen, Tyler (May 14, 2021) "BioCryst Pharmaceuticals expands in Birmingham." {{BBJ}}
* Patchen, Tyler (May 14, 2021) "BioCryst Pharmaceuticals expands in Birmingham." {{BBJ}}
* Ezzone, Zac & Laurel Thrailkill (April 20, 2023) "Pharma with Bham presence takes $300M loan to pay down debt." {{BBJ}}
* Ezzone, Zac & Laurel Thrailkill (April 20, 2023) "Pharma with Bham presence takes $300M loan to pay down debt." {{BBJ}}
* Ezzone, Zac (November 6, 2023) "BioCryst pays $5M upfront in licensing deal for vision-loss treatment." {{BBJ}}
* Thrailkill, Laurel (November 7, 2023) "Major biotech company to get $1.8M in tax incentives from Hoover." {{BBJ}}
* Thrailkill, Laurel (November 7, 2023) "Major biotech company to get $1.8M in tax incentives from Hoover." {{BBJ}}
* Ezzone, Zac (January 10, 2024) "Biotech firm with Birmingham facility cuts R&D jobs." {{BBJ}}


==External links==
==External links==

Latest revision as of 17:00, 11 January 2024

BioCryst logo.png

BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) is a pharmaceutical research company founded in 1986 in Birmingham as a spin-off of UAB research conducted by Charles Bugg and John Montgomery. William Spencer III, who had been involved in the launch of Molecular Engineering Associates, helped the company raise start-up investments.

BioCryst went public in 1994 and moved its headquarters to Durham, North Carolina in 2010. It maintains a 35,000 square-foot "Discovery Research Center and Laboratory Center of Excellence" (or "Discovery Center of Excellence") with approximately 60 employees at 2100 Riverchase Center in Riverchase Corporate Park. The center is headed by chief discovery officer Yarlagadda Babu.

Formerly headquartered at 2190 Parkway Lake Drive, BioCryst develops and manufactures various types of prescription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.

BioCryst planned to merge with Idera Pharmaceuticals of Exton, Pennsylvania in 2018, but the move was blocked by shareholders in July.

In April 2023 BioCryst negotiated a $450 million 5-year financing agreement with Pharmakon Advisors of New York City. The deal provided funds to repay $241.8 million in existing debts to Athyrium Capital Management.

Later that year, BioCryst made plans to expand its research and manufacturing facility to 49,054 square feet, occupying the entire 2100 Riverchase Center building. The City of Hoover provided $1,828,470 in tax abatements over 10 years to support the expansion. In early 2024 the company announced that it would postpone that expansion amid a larger reduction in research and development spending.

Chief executives

Products

BioCryst has developed several drug treatments:

  • BCX-1777 ("Fodosine"), IV, for treatment of T-cell leukemia
  • BCX-1812 ("Peramivir"), for treatment of seasonal/life-threatening influenza
  • BCX-4161 ("Avoralstat") for treatment for vision loss related to diabetes
  • BCX-4208 ("Ulodesine"), for treatment of autoimmune diseases/transplantation/Hepatitis C
  • BCX-7353 ("Orladeyo"), for prevention of recurrent hereditary angioedema attacks

References

External links

Retrieved from "http://bhamwiki.com/w/index.php?title=BioCryst&oldid=211433"